Gan & Lee's GZR18, GZR4, and GZR101 Injections Meet Phase 2 Primary Endpoints

Recently, Gan & Lee Pharmaceuticals announced promising results from Phase 2 clinical trials for three of its innovative diabetes treatments: the bi-weekly GLP-1 receptor agonist GZR18 injection, the once-weekly basal insulin analog GZR4 injection, and the premixed dual insulin analog GZR101 injection. These trials, conducted on adult patients with Type 2 diabetes in China, showcased the superior efficacy of these treatments in lowering glycated hemoglobin (HbA1c) levels compared to existing therapies.

The bi-weekly GLP-1 receptor agonist GZR18 injection demonstrated notable success in a 24-week treatment regimen. Patients receiving GZR18 showed a more significant reduction in HbA1c and body weight compared to those treated with semaglutide (Ozempic®). This indicates that GZR18 could be a more effective option for managing blood sugar levels and reducing weight in patients with Type 2 diabetes, offering an alternative to current GLP-1 receptor agonists.

In a separate 16-week trial, the once-weekly insulin analog GZR4 injection was tested on patients with uncontrolled diabetes who were already on basal insulin therapies. The results were impressive, with GZR4 showing superior HbA1c reduction compared to insulin degludec (Tresiba®). This suggests that GZR4 might offer a better glycemic control option for patients struggling with maintaining their blood sugar levels on existing basal insulins.

Another 16-week clinical trial focused on the premixed dual insulin analog GZR101 injection, designed to offer both basal and prandial insulin coverage. This study compared GZR101 to insulin degludec/insulin aspart (Ryzodeg®). GZR101 demonstrated superior efficacy in reducing HbA1c and postprandial glucose levels, indicating that it might provide a more effective comprehensive insulin therapy for patients managing Type 2 diabetes.

Gan & Lee Pharmaceuticals, listed on the Shanghai Stock Exchange as 603087, has thus achieved a significant milestone with these positive outcomes from its Phase 2 trials. These results not only underscore the potential of GZR18, GZR4, and GZR101 to offer better therapeutic options for Type 2 diabetes management but also highlight the company's commitment to advancing diabetes care through innovative treatments.

This progress could lead to improved patient outcomes and a broader range of treatment options for those managing Type 2 diabetes. Gan & Lee's successful development of these drugs marks an important step in addressing the global diabetes epidemic, potentially providing patients with more effective tools to control their blood sugar levels and maintain better overall health.